Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Dec

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma

Tanning Bed Exposure and Melanoma Risks

FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma

HER2-Positive Breast Cancer FDA Approves T-DXd Plus Pertuzumab

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers